Retention of new AEDs in institutionalized intellectually disabled patients with epilepsy  by Carpay, J.A. et al.
Retention of new AEDs in institutionalized intellectually disabled patients
with epilepsy
J.A. Carpay a,*, K. Aalbers a, G.A. Graveland b, M. Engelsman c
a Tergooiziekenhuizen, Department of Neurology, Blaricum, The Netherlands
bKempenhaeghe Epilepsy Center, Location Hans Berger Kliniek, Breda, The Netherlands
c SEIN Epilepsy Center, Heemstede, The Netherlands
Seizure 18 (2009) 119–123
A R T I C L E I N F O
Article history:
Received 5 May 2008
Received in revised form 3 July 2008






A B S T R A C T
Purpose: To assess the long-term usefulness of ‘new anti-epileptic drugs (AEDs)’ (lamotrigine, topiramate,
levetiracetam, gabapentin and pregabalin) in institutionalized intellectually disabled patients.
Information from RCTs is lacking in this population with severe intellectual and behavioural disabilities.
Methods: Retrospective study. Data from the medical ﬁles and the pharmacy databases of 118
institutionalized intellectually disabled patients who had ever used at least one of the new AEDs were
analyzed. The main evaluation parameters were the duration of use (using Kaplan–Meier survival
estimates) and the reason for discontinuation (lack of efﬁcacy, occurrence of adverse events, or both) of
the new AEDs. Drug continuation was based on the evaluation of treatment results by experienced
epileptologists, and not on ﬁxed criteria.
Results: New AEDs were generally tried only after a substantial number of other regimens (with classic
AEDs) had failed. The most frequently used new AEDs were lamotrigine (68%) and levetiracetam (58%),
followed by topiramate (28%) and gabapentin (8%). The 3-year retention rates were 70% (lamotrigine),
52% (levetiracetam), 51% (topiramate) and 33% (gabapentin). Discontinuation due to ‘‘lack of efﬁcacy’’
occurred in 61% (topiramate), 60% (lamotrigine) and 42% (levetiracetam) of the cases. Discontinuation
due to adverse events occurred in 42% (levetiracetam), 33% (topiramate) and 28% (lamotrigine).
Conclusions: Treatment of epilepsy with new AEDs was quite often successful in this very therapy-
resistant population.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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journa l homepage: www.e lsev ier .com/ locate /yse izEpilepsy is common in patients with intellectual disabilities.1
More than 30% of these patients develop seizures,2 with a
prevalence of up to 50% in institutionalized patients.1 Epilepsy
in these patients is often characterized by multiple concurrent
seizure types2–5 and its severity increases with the severity of the
mental handicap, probably reﬂecting the amount of underlying
brain damage.
Treatment of epilepsy in intellectually disabled patients is not
essentially different from treatment in intellectually normal
patients,6 but the severity of their epilepsy often requires
administration of multiple anti-epileptic drugs (AEDs), and
frequently many (combinations of) products are started before
seizure control is considered acceptable. However, a substantial
proportion of patients, particularly those with severe intellectual* Corresponding author at: Tergooiziekenhuizen, Rijksstraatweg 1, 1261 AN
Blaricum, The Netherlands. Tel.: +31 35 539 15 51.
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1059-1311/$ – see front matter  2008 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2008.07.007disability, continue to suffer from poorly controlled seizures
despite the use of two or more AEDs.7,8
The introduction of the newer AEDs, starting with lamotrigine
(registered in the Netherlands in 1996), followed by topiramate
and gabapentin (both registered in 1999), levetiracetam (regis-
tered in 2000) and pregabalin (registered in 2004), offered new
opportunities for treatment. However, the use of the newer AEDs in
intellectually disabled patients cannot be regarded as truly
evidence-based. The randomized controlled clinical trials, per-
formed to support the registrations of these products, excluded
subjects with substantial intellectual disabilities for both ethical
and practical reasons. To our knowledge no post-marketing
randomized controlled trials have appeared in the published
literature. A 2007 Cochrane review to assess the data available
from randomized controlled trials of AEDs in patients with
epilepsy and intellectual disabilities has been published.9 The
authors conclude that studies were heterogeneous and that
concerns over side effects may continue to exist despite the
published data. However, AEDswere found effective in this speciﬁc
population and the reported side effects were roughly similar tovier Ltd. All rights reserved.
Table 1
Description of the patient population
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obtained from publications on the results of prospective open
studies or retrospective studies with lamotrigine,10–13 levetirace-
tam,14,15 topiramate,16–18 gabapentin,19 and gabapentin compared
with lamotrigine,20,21 and from post-marketing surveillance.
Recently a study has been published on the long-termuse of the
new AEDs gabapentin, lamotrigine, levetiracetam, oxcarbazepine,
tiagabine and topiramate in adult patients with chronic epilepsy
and learning disabilities in a single UK institution.22 From this
study it was concluded that gabapentin and tiagabine had little
impact on epilepsy treatment, whereas oxcarbazepine, levetir-
acetam, lamotrigine and topiramate were used for more than 2
years in 45–85% of the patients.
In order to increase the amount of data on the use of new AEDs
in intellectually disabled patients, we performed the present
retrospective study in three institutions in the Netherlands. The
aim of this study was to establish the long-term retention of new
AEDs (i.e. registered in the Netherlands after 1996) in institutio-
nalized intellectually disabled patients.
1. Materials and methods
The study was performed as a retrospective study on the use of
new anti-epileptic drugs (new AEDs, deﬁned as AEDs registered in
the Netherlands since 1996) in institutionalized intellectually
disabled patients in three Dutch centres in the Netherlands (De
Amerpoort, Baarn; Sherpa, Baarn; Merwebolder, Sliedrecht and
SOVAK, Terheijden, the Netherlands). There were about 1700
inhabitants in these institutions. All patients with epilepsy in these
institutions are treated by a neurologist (JC, ME or GG) with special
expertise in epilepsy (epileptologist). We included only those
patients who had ever been treated with one of the new AEDs.
New AEDs were registered in the Netherlands in the following
years:N 118
Lamotrigine 1996Age (years)
Mean  S.D. 38.7  12.1Topiramate 1999
Range 9–61Gabapentin 1999Weight (kg)Levetiracetam 2000
Mean  S.D. 61.6  15.5




Subjects using concomitant medication for behavioural
disorder(s)
n = 14 (11.9%)
Benzodiazepines n = 8
Antipsychotics n = 4
Antidepressants n = 3
















Unknown 1.7The only selection criterion for inclusion in the study was the
current or past use of new AEDs. Oxcarbazepine was not
considered a new AED, as it is frequently used as a – possibly
less toxic – replacement for carbamazepine and not as an
additional AED when seizure control is inadequate.22 The main
source of information in this study consisted of the patients
medical ﬁles, which were routinely completed by attending
neurologist. The patient charts were checked for completeness
using the institutions pharmacy databases. Treatment of the
patients reﬂected normal clinical practice without the use of a
formal protocol. AEDs were continued when the neurologist (in
close collaboration with the patients carers) noted a signiﬁcant
improvement in seizure control, without unacceptable adverse
effects. The participating neurologists were reluctant to continue
new AEDs if there was no substantial improvement in seizure
control. Formal criteria for success based on seizure counts (such as
a 50% reduction in seizure frequency) were not used, because in
this setting reliable seizure counts are difﬁcult to achieve and may
not reﬂect improvement from a patients individual perspective.
Patients were seen at regular intervals according to their clinical
needs. The review period covered all available data on AED use
from the admission date to the institution (which may have beenmany years prior to the start of the study), until the cut-off date of 5
February 2007.
Data were collected on patient characteristics (age, weight, sex),
severity of intellectual disability (based on IQ estimates), use of
concomitant medication for behavioural disorders, and current use
andhistoryofuse ofAEDs. Themainevaluationparameterswere the
duration of use of the new AEDs and the reason for discontinuation
(lackof efﬁcacy, occurrence of adverse events, or both). The duration
of use was analyzed using Kaplan–Meier survival estimates. A
Kaplan–Meier survival life tablewas constructed and plotted for the
retention of lamotrigine, topiramate, levetiracetam and gabapentin
(no analysiswas performed for pregabalin, since this compoundwas
only registered in 2004 and its usewas limited to very fewpatients).
Duration of retention was calculated as the time between the start
date and the stop date of the AED concerned. If patients were still
taking the drug at the time of data collection, or if a patient had died
during the observation period, the data were censored. The
differences in retention rates obtained were analyzed statistically
using a log rank test.
2. Results
Adescriptionof the studypopulation of 118patients is presented
inTable1.Meanageof thepatientswas38.7years (S.D. = 12.1; range
9–61 years), with ameanweight of 61.6 kg (range 24–99 kg). A total
of 85% of the patients had moderate to severe intellectual disability
(based on IQ estimates). Seven patients (5 using lamotrigine and 2
using levetiracetam) died during the review period; none of the
deathswas considered to be related to AED treatment. In addition, 4
patients (2 using lamotrigine and 2 using lamotrigine, topiramate
and levetiracetam) were lost to follow-up. A small number of
Table 2





Ever started Ordera Continued Observation period (range
in months)
n % Median Range n %b Minimum Maximum
Lamotrigine 101.5 2.3 80 68 6 2–8 55 69 1 156
Topiramate 78.0 1.2 33 28 7 2–9 16 48 1 69
Gabapentin 1911.1 26.6 9 8 7.5 4–9 3 33 1 58
Levetiracetam 1301.5 26.4 68 58 7 2–10 42 62 1 52
Patients can be listed more than once in this table, when they used >1 new AED.
a The number of AEDs that have been tried, including the AED concerned.
b Relative to the number of the subjects who started.
Fig. 2. Reasons for discontinuation of treatment with lamotrigine, topiramate and
levetiracetam (number of patients discontinuing treatment is given inside the
vertical bars.)
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disorder(s), including benzodiazepines (n = 8), antipsychotics
(n = 4) and antidepressants (n = 3). In addition to the newer AEDs,
many patients continued using one of the classic AEDs, with
carbamazepine and valproate being the most frequently used
compounds (used by 58.8 and 43.0% of the patients, respectively).
The longest follow-up was possible for patients using lamo-
trigine (almost 14 years in one case), since this AED became
available in the mid-90s. Only 3 of the newer AEDs (lamotrigine,
topiramate and levetiracetam) were used in a sufﬁcient number of
patients for adequate analysis; gabapentin and pregabalin were
only used in 9 and 7 patients, respectively. Most of the patients had
tried many different AEDs andmany have also usedmore than one
of the newer AEDs. Lamotrigine was started on average as the 6th
AED (range 2–8). The other new AEDs were chosen at a later stage
(median as 7th AED). This order of selection of newer AEDs is
largely related to their year of introduction, though other factors
may also have played a role. The dose regimens used were within
the dose ranges recommended in the prescribing information.
The most frequently used new AEDs were lamotrigine and
levetiracetam, which were started in 68 and 58% of the patients,
respectively (see Table 2).
Retention rates were estimated with Kaplan–Meier survival
analysis (Fig. 1). It should be noted that the number of patients
treated with gabapentin was very low, making the estimates less
reliable. The 2- and 3-year retention rates of lamotrigine were the
highest, with 75 and 70%, respectively. The 2- and 3-year retention
rates of the other AEDs were 59 and 52% (levetiracetam), 63 and
51% (topiramate) and 44 and 33%, respectively (gabapentin).
A log rank test showed statistically signiﬁcant differences for
retention rates of LTG vs GBP (p = 0.02), and for LTG vs TPM
(p = 0.04).
The retention rate is a composite marker of efﬁcacy and safety.
To investigatewhether discontinuation of treatmentwas related toFig. 1. Kaplan–Meier survival plots for lamotrigine (LTG), levetiracetam (LEV),
topiramate (TPM), and gabapentin (GBP). (j) Censored value. Lengths of observation
periods are related to the number of years new AEDs were available.insufﬁcient efﬁcacy or occurrence of adverse events, the reasons
for discontinuation were categorized as ‘‘lack of efﬁcacy’’,
‘‘occurrence of adverse events’’, or ‘‘both reasons combined/other
reasons’’. The frequency distribution of these reasons for dis-
continuation were different for lamotrigine, topiramate and
levetiracetam (the number of patients using gabapentin and
pregabalin were too small for accurate analysis). In the lamo-
trigine-treated patients ‘‘lack of efﬁcacy’’ was more frequently the
reason for discontinuation (60% of the cases), with a lower rate of
discontinuation due to adverse events (28% of the cases), whereas
in the levetiracetam-treated patients ‘‘lack of efﬁcacy’’ and
‘‘adverse events’’ were each the cause for discontinuation in 42%
of the cases (see Fig. 2). For topiramate these percentages were 61
and 33%, respectively.
The nature of the adverse events was not remarkable different
from that in the intellectually normal population with epilepsy.
Some adverse events were classiﬁed as being related to behaviour,
mood or cognition (12 in patients using levetiracetam, 8 in patients
using lamotrigine, 7 in patients using topiramate, 1 in a patient
treated with topiramate and gabapentin and 1 in a patient using
gabapentin).
3. Discussion
The optimal management of epilepsy with use of AEDs in
intellectually disabled patients is challenging due to the severity of
the epilepsy and the associated medical and psychiatric pro-
blems.2,4 Because RCTs in epilepsy for the intellectually disabled
are lacking, post-marketing studies systematically assessing the
usefulness of new AEDs are of interest. Our study shows that new
AEDs were quite often useful in this therapy-resistant and
substantially intellectually disabled population. Lamotrigine and
levetiracetam were the most often used new AEDs. Three-year
retention rates were comparable to those previously reported in
J.A. Carpay et al. / Seizure 18 (2009) 119–123122patients with normal intellectual abilities and in intellectually
disabled patients.22,27,31
From a total of about 1700 patients living in the institutions
participating in our study, we estimate that about 500 were using
AEDs for epilepsy. The 118 patients who had ever used one of the
new AEDs can be considered rather low, pointing to a conservative
approach to epilepsy treatment in this population.At the timeof this
study, only carbamazepine, valproate and lamotrigine were
recommended as ﬁrst-line AEDs in the Dutch Guidelines for the
treatment of epilepsy.23 In a 2006 revision of these guidelines24
oxcarbazepine was added as a ﬁrst-line AED. Both versions of the
guidelines23,24 state that there are no controlled studies with
sufﬁcient evidence to select a ﬁrst-choiceAED for add-on treatment.
In the present study choice of a particular new AED has been
partly determined by the chronological availability of the products,
though other factors, such as knowledge of the product (due to the
extend of marketing), positive experience with the compound, and
ideas about relative efﬁcacy and safetymay also have played a role.
Patients starting treatment with the newest products are likely to
have ﬁrst been treated with the earlier registered new AEDs (e.g.
lamotrigine) and may have been more therapy-resistant.
The most frequently used new AEDs were lamotrigine (started
in 68% of the patients) and levetiracetam (started in 58% of the
patients), followed by topiramate (started in 28% of the patients).
The relatively low use of topiramate, despite the fact that it was
already registered in 1999, may be due to its reputation of
increased toxicity in this patient population.18 The limited use of
gabapentin, whichwas also available since 1999, may be related to
its reputation of low efﬁcacy in intellectually disabled patients.25
Few studies have addressed retention rates in this speciﬁc
subpopulation of severely intellectually disabled patients with
(intractable) epilepsy. In a publication by Simister et al.22 on a
similar speciﬁc population of intellectually disabled patients with
epilepsy in the UK, comparable results were obtained, with 2-year
retention rates of 57% (lamotrigine), 45% (topiramate) and 56%
(levetiracetam). We found retention rates which were at least as
good, conﬁrming a fair chance of success when one of the new
AEDs is tried in this therapy-resistant subpopulation.
The retention rates obtained for lamotrigine and topiramate in
our study are slightly higher than those reported in other series of
patients with epilepsy. An important difference between these
series and ours is the exclusive selection of cases with severe
intellectual disability in our series. Others reported retention rates
for lamotrigine of 40–60% (after 1 year) and 29% (after 3 years),26,27
and for topiramate of 40–60% (after 1 year), 45% (after 2 years), 30–
38% (after 3 years) and 30% (after 4 years).26–29 For levetiracetam
the retention rates in the general population were similar to those
obtained in our study, viz. 60–75% (after 1 year), 58% (after 3 years)
and 32% (after 5 years).26,30,31 Recently Chung et al. reported
remarkably high retention rates for lamotrigine at 2 years (74%),
with rates for topiramate (44%) and levetiracetam (54%) more in
line with other studies.32 Bootsma et al. compared retention rates
for lamotrigine at 1 (74%) to 4 years (56%), and found that patients
with normal cognitive function were more likely to continue the
drug than patients with metal retardation.33 From the same
tertiary epilepsy centre, retention rates for levetiracetam (46%) and
topiramate (38%) at 2 years were reported.34 The high retention
rates for levetiracetam and topiramate in our group of severely
intellectually disabled patients may be due to more severe
epilepsies with greater need for additional seizure suppression,
better tolerance (or greater likelihood of missing cognitive and
other adverse effects), and/or more specialized neurological care.
As in the most published long-term follow-up studies the
effects of the new AEDs on seizure control were not quantiﬁed by
calculation of reductions in seizure frequency. Especially in thispopulation seizure counts may be very unreliable, and may not
reﬂect the impact on a patients individual functioning or quality of
life. Although in this study retention ultimately was based on one
neurologist’s subjective assessment, in our view it reﬂects the best
possible clinical practice.
Some differences in the reasons for discontinuation of new
AEDs were observed. Lamotrigine and topiramate were discon-
tinued due to lack of efﬁcacy in 60 and 61% of the cases, whereas in
the levetiracetam-treated patients this occurred in only 42% of the
cases. Discontinuation because of adverse events occurred more
frequently in the levetiracetam-treated patients (42% of the cases),
compared to 33% in the topiramate-treated patients and 28% in the
lamotrigine-treated patients. The incidence of adverse effects
induced by topiramate does not conﬁrm the reputation of
topiramate of having a relatively high toxicity in intellectually
disabled patients,18 and is also not in line with the relatively high
incidence of adverse events reported in the publications by
Simister et al.22 and Bootsma.et al.28Wemay have used topiramate
more cautiously than others, using low dosages (mean 78 mg/day
or 1.2 mg/kg) and slow titrations schedules, thus achieving higher
retention rates.
Retrospective studies have obvious limitations. The open, non-
randomized design makes it impossible to deﬁnitely attribute
observed improvements or adverse effects to the AED used, or to
make meaningful head-to-head comparisons between new AEDs.
Major strengths of this study were its resemblance to the normal
clinical situation (there were no speciﬁc selection criteria for
inclusion or schedules for treatment) and the quality of the
documentation (records being kept for long periods of time; a
stable study population with very few patients lost to follow-up).
The effects of confounding factors such as severity of intellectual
disability, the number and types of previously used AEDs, the
number and types of currently used AEDs, use of concomitant
(psychotropic or other medication) and age on the retention rates
of the new AEDs were beyond the scope of this study.
The present study describes the usefulness of new AEDs in
intellectually disabled patients in clinical practice. The calculated
retention rates, which represent a composite measure of efﬁcacy
and safety over time, are relevant in assessing the value of a
particular AED treatment.35 We conclude that in this population a
history of failure of a substantial number of (classical) AED
regimens should not result in therapeutic nihilism.
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